Skip to main content

Fiscal Wizard · Single-issue tearsheet

BTAI / Jun 21, 2026 Run #7452

BTAI

BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Composite verdict

F 8.9 / 100
Bearish setup · Reversal 13 drivers · 7 gates blocking
  • Williams %R
  • Double 7s
  • Connors RSI(2)
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 67th of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 20 signals100% Bear
Momentum Bearish 26Mean-reversion Bearish 30
  • Late-stage trendTrend signals have been live for 188 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

17.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Return on Assets 0
EPS Growth (YoY) 100
Free Cash Flow Yield 0
Capex to Sales 75
FCF Margin 0

Technicals Bearish

0.1 / 100

Bearish setup leads (Williams %R, Double 7s, Connors RSI(2)); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Williams %R 7
Coppock Curve 15
Double 7s 15

Risk Gates

7 blocking 5 caution

7 guards active, 20 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Debt-to-Assets Blocking

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for BTAI.